Skip to main content

Table 1 Correlation between eIF4A1 expression and clinical characteristics of PDAC patients

From: Targeted intervention of eIF4A1 inhibits EMT and metastasis of pancreatic cancer cells via c-MYC/miR-9 signaling

Clinical characteristics

High-eIF4A1

Low-eIF4A1

P-value

Age, mean ± SD, years

66.04 ± 9.69

64.10 ± 10.07

0.482

Male, n (%)

13 (56.53%)

21 (70.00%)

0.311

Overall survival, median, months

6.0 (4.0, 9.0)

9.0 (8.0, 15.5)

0.006b

Differentiation status

 

0.523

 Well differentiated

11 (20.75%)

17 (32.08%)

 

 Moderately to poorly differentiated

12 (22.64%)

13 (24.53%)

Tumor size, mean ± SD, cm

4.57 ± 1.40

3.75 ± 1.28

0.032b

Recurrences, n (%)

17 (73.91%)

20 (66.67%)

0.569

Location

 

0.267

 Head, n (%)

15 (28.30%)

18 (33.96%)

 

 Body/tail, n (%)

7 (13.21%)

20 (37.74%)

Diffusion involvement, n (%)

1 (1.89%)

2 (3.77%)

TNM stagea

 

0.077

 I–II stage, n (%)

14

24

 

 III–IV stage, n (%)

9

5

Lymph node metastasis, n (%)

14 (63.64%)

10 (35.71%)

0.0498*

Vascular Infiltration, n (%)

10 (43.48%)

3 (10.00%)

0.272

  1. aNCCN Version 3.2019 pancreatic adenocarcinoma
  2. bP < 0.05, significant difference